SAPHO Syndrome Complicated by Lesions of the Central Nervous System Successfully Treated with Brodalumab

Figure 2

Changes over time in BASDAI and CRP during the therapy with Brodalumab. At 0 weeks, subcutaneous injection of Brodalumab 210 mg was initiated (arrow) and repeated weekly for two weeks. After loading, it was maintained by injection every two weeks.